Brief: Chinook Therapeutics To Present Updated Data From Zigakibart Phase 1/2 Trial
12/06/2023 21:03
June 12 (Reuters) - Chinook Therapeutics Inc KDNY.O :
* CHINOOK THERAPEUTICS TO PRESENT UPDATED DATA FROM
ZIGAKIBART
(BION-1301) PHASE 1/2 TRIAL IN PATIENTS WITH IGA NEPHROPATHY
(IGAN) AT THE 60TH EUROPEAN RENAL ASSOCIATION (ERA) CONGRESS
* CHINOOK THERAPEUTICS INC - ZIGAKIBART TREATMENT CONTINUES
TO
DEMONSTRATE RAPID AND SUSTAINED REDUCTIONS IN MECHANISTIC
BIOMARKERS
* CHINOOK THERAPEUTICS INC - ZIGAKIBART IS WELL-TOLERATED,
WITH NO
ADAS OBSERVED OR TREATMENT DISCONTINUATIONS DUE TO ADVERSE
EVENTS
Source text for Eikon: ID:nGNX15YC2
Further company coverage: KDNY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chinook Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Chinook Therapeutics
Chinook Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Chinook Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: Chinook Therapeutics Announces First Patient Enrolled In Phase 3 Of Zigakibart
Brief: Muddy Waters- Remains Short On Chinook Therapeutics Inc